INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 220 filers reported holding INOVIO PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 1.34 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $161,099 | -46.1% | 414,139 | -38.2% | 0.00% | – |
Q2 2023 | $298,803 | -89.6% | 669,960 | -81.0% | 0.00% | – |
Q1 2023 | $2,886,915 | -25.1% | 3,520,627 | +42.5% | 0.00% | – |
Q4 2022 | $3,853,912 | +32.9% | 2,470,457 | +47.0% | 0.00% | – |
Q3 2022 | $2,899,000 | +64.8% | 1,680,383 | +65.2% | 0.00% | – |
Q2 2022 | $1,759,000 | -66.2% | 1,017,135 | -29.9% | 0.00% | -100.0% |
Q1 2022 | $5,207,000 | +62.3% | 1,450,537 | +125.6% | 0.00% | – |
Q4 2021 | $3,209,000 | +68.5% | 642,899 | +141.8% | 0.00% | – |
Q3 2021 | $1,904,000 | -53.2% | 265,919 | -39.4% | 0.00% | – |
Q2 2021 | $4,071,000 | -30.9% | 439,074 | -30.9% | 0.00% | – |
Q1 2021 | $5,893,000 | +582.9% | 635,073 | +551.1% | 0.00% | – |
Q4 2020 | $863,000 | -96.4% | 97,534 | -95.3% | 0.00% | -100.0% |
Q3 2020 | $24,186,000 | +180.1% | 2,085,043 | +550.8% | 0.00% | +300.0% |
Q2 2020 | $8,634,000 | +1334.2% | 320,388 | +295.6% | 0.00% | – |
Q1 2020 | $602,000 | +452.3% | 80,979 | +145.6% | 0.00% | – |
Q4 2019 | $109,000 | -27.8% | 32,969 | -55.5% | 0.00% | – |
Q3 2019 | $151,000 | -30.4% | 74,137 | +0.0% | 0.00% | – |
Q2 2019 | $217,000 | -68.4% | 74,123 | -59.7% | 0.00% | – |
Q1 2019 | $686,000 | +216.1% | 183,839 | +237.1% | 0.00% | – |
Q4 2018 | $217,000 | -37.6% | 54,529 | -12.6% | 0.00% | – |
Q3 2018 | $348,000 | -22.5% | 62,396 | -45.6% | 0.00% | – |
Q2 2018 | $449,000 | +13.7% | 114,660 | +36.6% | 0.00% | – |
Q1 2018 | $395,000 | +223.8% | 83,920 | +184.5% | 0.00% | – |
Q4 2017 | $122,000 | -41.1% | 29,497 | -9.7% | 0.00% | – |
Q3 2017 | $207,000 | +78.4% | 32,648 | +121.9% | 0.00% | – |
Q2 2017 | $116,000 | -38.3% | 14,713 | -47.9% | 0.00% | – |
Q1 2017 | $188,000 | +9.9% | 28,256 | +14.6% | 0.00% | – |
Q4 2016 | $171,000 | +87.9% | 24,651 | +153.3% | 0.00% | – |
Q3 2016 | $91,000 | -53.6% | 9,733 | -54.2% | 0.00% | – |
Q2 2016 | $196,000 | +345.5% | 21,230 | +328.0% | 0.00% | – |
Q1 2016 | $44,000 | -65.6% | 4,960 | -74.0% | 0.00% | – |
Q4 2015 | $128,000 | +456.5% | 19,108 | +369.4% | 0.00% | – |
Q3 2015 | $23,000 | -95.9% | 4,071 | -94.0% | 0.00% | – |
Q2 2015 | $558,000 | +541.4% | 68,418 | +544.5% | 0.00% | – |
Q1 2015 | $87,000 | -47.0% | 10,616 | -40.5% | 0.00% | – |
Q4 2014 | $164,000 | +248.9% | 17,850 | +273.6% | 0.00% | – |
Q3 2014 | $47,000 | -70.1% | 4,778 | -67.0% | 0.00% | – |
Q2 2014 | $157,000 | – | 14,460 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
Beck Bode, LLC | 41,218 | $33,799 | 0.01% |